Our technologies

Biopharm

Voltage-Gated Sodium Channel Knockout Mice: Tools for Developing Therapeutics for the Treatment of Pain

Voltage-Gated Sodium Channel Knockout Mice: Tools for Developing Therapeutics for the Treatment of PainAvailable for: Non-exclusive licensingSummaryScientists at University College London have developed Voltage-Gated Sodium Channel subtype specific conditional knockout mice which provide invaluable tools for the development of therapeutics for the treatment of pain.The Technology and its AdvantagesUniversity College London have developed the following

More info »

Engineering

Superior X-Ray Imaging for Early Detection of Breast Cancer

Superior X-Ray Imaging for Early Detection of Breast CancerAvailable For: Licensing and co-developmentSummaryProfessor Robert Speller and his team at University College London have developed a novel phase contrast x-ray technology with the potential for improved image quality and enhanced diagnostic potential when applied to mammography. This technology will provide earlier more accurate detection of breast

More info »

Biopharm

New lentiviral platform eliminating packaging sequences from the transcribed DNA region

Available for: Exclusive/Non-exclusive LicensingSummaryAll lentiviral vectors described to date contain packaging sequences necessary for the viral RNA genome to be assembled into viral particles. These sequences are unnecessarily reverse transcribed into DNA and permanently integrate into target cells. The researchers at UCL Institute of Child Health have developed a lentiviral platform which does not reverse

More info »

Biopharm

Novel Therapy for Polycystic Kidney Disease (PKD)

Available for: Exclusive/Non-Exclusive LicensingSummaryPolycystic kidney disease is the most common inherited cause of kidney failure, affecting 1 in 1000 adults and children worldwide. It is characterized by the growth of multiple cysts leading to loss of normal kidney structure and functions and often results in end-stage renal disease. The researchers at UCL Institute of Child

More info »

Biopharm

Formulations for the Prevention of Neural Tube Defects

Formulations for the Prevention of Neural Tube DefectsAvailable for: LicenseSummaryExploring ways to prevent birth defects,researchers at the UCL Institute of Child Health have discovered novel supplements that if taken in pregnancy can reduce the chance of the baby having neural tube defects such as spina bifida or anencephaly. These are important in pregnancies where folic

More info »

Biopharm

Magnetic Targeting of Cells using MR Imaging Gradients

Magnetic Targeting of Cells using MR Imaging GradientsAvailable for: Co-development and/or licensingSummary UCL researchers have developed a novel technique to magnetically targetcells using MRI. This allows image guided targeted delivery of cells to sites of the body which cannot be reached with external permanent magnets.The Technology and its AdvantagesAn increasing number of clinical trials assess

More info »

Biopharm

Leukocyte labelling for detecting inflammation

Available for: Exclusive/Non-Exclusive licensingSummaryInflammation plays a role in many diseases including sight-threatening diseases of the eye such as uveitis. Recently, inflammation has also been shown to drive the processes of pathological angiogenesis in Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). Current methods for monitoring inflammation have limits and include direct visualisation by endoscope, PET

More info »

Biopharm

Treatment of fibrosis with ALDH inhibitors

Treatment of fibrosis with ALDH inhibitorsAvailable for: Exclusive LicensingSummaryFibrosis is the formation of excess fibrous connective tissue in response to injury and inflammation. If it happens in response to injury it is also referred to as scarring. Fibrosis is associated with conditions such as cystic fibrosis, cirrhosis, mucous membrane pemphigoid (MMP), pulmonary fibrosis and scleroderma.

More info »

Biopharm

H4R antagonists for uveitis and other inflammatory diseases

Available For: Exclusive LicensingSummaryHistamine is a pleiotropic mediator involved in a variety of physiological processes including neurotransmission, endocrine and vascular processes. It also plays a key role in inflammation and binding to one of its four receptors (H1R-H4R). Researchers at UCL Institute of Ophthalmology have shown that targeting H4R receptor in the central nervous system

More info »

Biopharm

Lrg-1 antagonists: Direct effect upon cancer cells

LRG1 antagonists for neovascularisation, cancer and aberrant scaring Available for: Exclusive/Non-exclusive licensing SummaryThe formation of new blood vessels by angiogenesis is a key feature of number of diseases including Age-related Macular Degeneration (AMD), Proliferative Diabetic Retinopathy (PDR), atherosclerosis, rheumatoid arthritis and cancer. Vascular Endothelial Growth Factors (VEGFs) and their receptors have been previously identified as

More info »

View by:

Technology area:
Theme:
Market:
Search: